Dallas-based Celanese agreed to supply its VitalDose drug delivery platform for use as a component in Gluakos’ iDose TR. The iDose TR serves as a micro-invasive intraocular implant for lowering intraocular pressure. It treats patients with primary open-angle glaucoma or ocular hypertension.
According to a news release, iDose TR addresses patient non-adherence and chronic side effects through all-day, long-duration therapy. In February, Glaukos submitted a New Drug Application (NDA) to the FDA. It remains under review.
Celanese designed VitalDose to provide reliable, controlled release. The company said sustained release represents an increasingly important approach to treating glaucoma. With VitalDose, continuous dosing could potentially reduce patient compliance and adherence issues, the company added.
“The inclusion of our VitalDose Platform in Glaukos’ iDose TR therapy furthers our mission to improve patient health in ophthalmology for those living with chronic eye diseases,” said Cyonna Holmes, global business strategy leader for ophthalmology at Celanese. “Our team is excited to support Glaukos as they continue to advance their efforts to bring iDose TR to patients who may need a new glaucoma treatment alternative.”
